Citations

Clear

815 citation(s) found for "Tang, Yu".

Robust Principal Component Analysis with Wavelet-Based Sparsity Promotion to Mitigate Reverberation Clutters for Ultrasound Attenuation Estimation
Lok, U‐Wai , Tang, Shanshan , Zhou, Chenyun , Watt, Kymberly D., Callstrom, Matthew R. , Trzasko, Joshua D. , Chen, Shigao , Lok, U-Wai , Gong, Ping , Huang, Chengwu , Yang, Lulu

Mayo Clinic

2022 IEEE International Ultrasonics Symposium (IUS) | December 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/ius54386.2022.9957606 Get It

Killian Jamieson Diverticulum, the Great Mimicker: A Case Series and Contemporary Review
Howell, Rebecca J. , Tang, Alice L. , Allen, Jacqui , Altaye, Mekibib , Bayan, Semirra L. , Belafsky, Peter C. , Cervenka, Brian , deSilva, Brad W. , Dion, Gregory R. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Giliberto, John Paul , Harmon, Jeffrey , Kasperbauer, Jan L. , Khosla, Sid , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Mayerhoff, Ross , Piraka, Cyrus , Rosen, Clark A. , Wahab, Shaun A. , Wilson, Keith , Wright, Stephen C. , Young, VyVy N. , Yuen, Sonia , Postma, Gregory N. , Howell, Rebecca , Bayan, Semirra, Belafsky, Peter , deSilva, Brad , Dion, Greg , Ekbom, Dale , Giliberto, John Paul , Kasperbauer, Jan , Kuhn, Maggie , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Tabangin, Meredith , Young, Vyvy , Yuen, Sonia , Bayan, Semirra , Amin, Milan R , Guardiani, Elizabeth , Kwak, Paul E. , Ma, Yue , Tabangin, Meredith E. , Wilson, Keith, Wright, S. Carter

Mayo Clinic

The Laryngoscope | December 1, 2022 | Volume: 133 | Issue: 9 | Pages: 2110-2115

10.1002/lary.30508 | PMID 36453465 Get It

ObjectiveTo assess barium esophagram (BAS) as a diagnostic marker for patients with Killian Jamieson diverticula (KJD).MethodsProspective, multicenter cohort study of individuals enrolled in the Prospective OUtcomes of Cricopharyngeus Hypertonicity (POUCH) Collaborative. Patient demographics, comorbidities, radiographic imaging reports, laryngoscopy findings, patient‐reported outcome measures (PROM), and operative reporting were abstracted from a REDCap database and summarized using means, medians, percentages, frequencies. Paired t‐tests and Wilcoxon Signed Rank test were used to test pre‐ to post‐operative differences in RSI, EAT‐10, and VHI‐10 scores. Diagnostic test evaluation including sensitivity, specificity, positive, and negative predictive value with 95% confidence intervals were calculated comparing BAS findings to operative report.ResultsA total of 287 persons were enrolled; 13 (4%) patients were identified with confirmed KJD on operative reports. 100% underwent open transcervical excision. BAS has a 46.2% (95% confidence interval [CI]: 23.2, 70.9) sensitivity and 97.8% (95% CI: 95.3, 99.0) specificity in detecting a KJD and 50% (95% CI: 25.4, 74.6) positive predictive value but 97.4% (95%CI: 94.8, 98.7) negative predictive value. Preoperatively, patients reported mean (SD) RSI and EAT‐10 of 19.4 (9) and 8.3 (7.5) accordingly. Postoperatively, patients reported mean (SD) RSI and EAT‐10 as 5.4 (6.2) and 2.3 (3.3). Both changes in RSI and EAT‐10 were statistically significant (p = 0.008, p = 0.03).ConclusionKJD are rare and represent <5% of hypopharyngeal diverticula undergoing surgical intervention. Open transcervical surgery significantly improves symptoms of dysphagia. BAS has high specificity but low sensitivity in detecting KJD.Level of Evidence4 Laryngoscope, 133:2110–2115, 2023
Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
Bhardwaj, Vaishali , Jalali, Shahrzad , Tang, Xinyi , Mukherjee, Prithviraj , Kim, Hyo-Jin, Mudappathi, Rekha , Wenzl, Kerstin , Novak, Anne J. , Ansell, Stephen M. , Bhardwaj, Vaishali , Villasboas, José C. , Yang, Zhi-Zhang , Mondello, Patrizia , Wang, Junwen , Krull, Jordan E.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2904-2905

10.1182/blood-2022-166450 Get It

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma
Sharma, Neeraj , Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Shivaram, Suganti, Kourelis, Taxiarchis , Kumar, Shaji , Sharma, Neeraj , Tang, Hongwei, Baughn, Linda B.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4209-4210

10.1182/blood-2022-166744 Get It

Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
Wu, Xiaosheng , Ruan, Gordon , Witter, Taylor L. , Gwin, Kimberly, Nowakowski, Kevin E., Abeykoon, Jithma P. , Tang, Xinyi , Yu, Yue , Dasari, Surendra , Ansell, Stephen M. , Schellenberg, Matthew J. , Manske, Michelle K. , Tang, Xinyi, Paludo, Jonas , Badley, Andrew D. , Witzig, Thomas E.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 42-43

10.1182/blood-2022-162574 Get It

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry
Abonour, Rafat , Durie, Brian G.M. , Gasparetto, Cristina, Narang, Mohit , Omel, James, Rifkin, Robert M. , Terebelo, Howard R. , Toomey, Kathleen, Slaff, Samantha, Danforth, Dailan, Chung, Weiyuan, Anand, Jasmeet, Yu, Edward, Tang, Derek, Jagannath, Sundar, Lee, Hans C. , Ailawadhi, Sikander , Gasparetto, Cristina , Hardin, James W. , Wagner, Lynne I. , Jagannath, Sundar

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 13256-13258

10.1182/blood-2022-158197 Get It

Lifetime Management of Aortic Stenosis: Transcatheter Versus Surgical Treatment for Young and Low-Risk Patients
Russo, Giulio , Tang, Gilbert H.L. , Sangiorgi, Giuseppe , Enriquez‐Sarano, Maurice , Maisano, Francesco , Pedicino, Daniela , Enriquez-Sarano, Maurice , Russo, Giulio , Maisano, Francesco , Taramasso, Maurizio

Mayo Clinic

Circulation: Cardiovascular Interventions | November 15, 2022 | Volume: 15 | Issue: 11 | Pages: 915-927

10.1161/circinterventions.122.012388 | PMID 36378737 Get It

Transcatheter aortic valve replacement is now indicated across all risk categories of patients with symptomatic severe aortic stenosis and has been proposed as first line option for the majority of patients >74 years old. However, median age of patients enrolled in the transcatheter aortic valve replacement low-risk trials is 74 years and transcatheter aortic valve replacement has never been systematically investigated in young low risk patients. Although the long-term data in surgical aortic valve replacement in young patients (age <75) are well known, such data remain lacking in transcatheter aortic valve replacement. In the absence of clear guideline recommendations in patients with challenging anatomies (eg, hostile calcium, bicuspid), it is important to know the potential advantages and disadvantages of each treatment and to consider how they might integrate with each other in the lifetime management of such patients. In this review, we discuss current outstanding issues on the management of severe aortic stenosis from a lifetime management perspective, particularly in terms of initial intervention and future reinterventions.
CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218)
Kizilbash, Sani H. , Sahebjam, Solmaz , Jaeckle, Kurt A. , Welch, Mary , Kong, Xiao–Tang , Holdhoff, Matthias , Lammers, Anita, Remick, Adam, Allred, Jacob B., McBrayer, Samuel K. , Kunos, Charles A., Adjei, Alex A. , Kizilbash, Sani H , Piccioni, David Eric , Villano, John L. , Reid, Joel M. , Port, John D. , Lanza, Ian R. , Shapiro, Geoffrey I.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii75-vii75

10.1093/neuonc/noac209.288 Get It

Abstract IDH mutant gliomas depend on glutaminase for glutamate/glutathione generation from glutamine because R-2-hydroxyglutarate inhibits branched chain amino acid transaminase mediated glutamate biosynthesis. Telaglenastat (CB-839 HCl) is a potent glutaminase-1 specific inhibitor which depletes tumor glutamate in orthotopic IDH mutant glioma PDX models and extends survival in these orthotopic models when added to radiation/temozolomide. NCI-10218 (NCT03528642) is a phase I clinical trial investigating the safety and tolerability of telaglenastat administered orally concurrently with standard doses of radiation (50.4 Gy, grade 2; 59.4 Gy, grade 3) and temozolomide (75 mg/m2 orally daily) in patients (age 16+) with previously untreated IDH mutant grade 2/3 astrocytoma. Telaglenastat dose was escalated in cohorts (400-800 mg twice daily) based on a standard 3 + 3 design to determine the recommended phase 2 dose (RP2D). Toxicities were graded per CTCAE v5.0. An expansion cohort additionally incorporated a seven-day run-in of telaglenastat monotherapy at RP2D prior to radiation to evaluate the pharmacodynamic impact of telaglenastat on plasma and tumor metabolites. 23 patients with IDH mutant astrocytoma (WHO grade 2, n = 5; WHO grade 3, n = 18) were accrued between December 2018 and January 2022 (Dose Escalation: 16; Dose Expansion: 7). Median age was 32 years (range 23-69 years). 61% were male and 70% were ECOG 0. No dose-limiting toxicities were observed. Grade 3/4 adverse events (independent of attribution) included: lymphopenia (3), neutropenia (2), leukocytosis (2), alanine transaminase elevation (2), thrombocytopenia (1), leukopenia (1), maculopapular rash (1), hyperglycemia (1), hyponatremia (1). The RP2D of concurrent telaglenastat was defined as 800 mg twice daily. Following peak absorption on Day 15 at RP2D, the mean (%CV) terminal elimination half-life in the plasma was 4.2 (53.5%) hours (range 2.1-7.1 hours). The Cmax, Tmax, oral clearance, and AUC were 1496 ng/mL, 4.0 hr, 93.6 L/hr/m2, and 7430 ng/mL*hr, respectively.
Selective decrease of donor-reactive T regs after liver transplantation limits T reg therapy for promoting allograft tolerance in humans
Tang, Qizhi , Leung, Joey , Peng, Yani , Sánchez‐Fueyo, Alberto , Lozano, Juan José , Lam, Alice, Lee, Karim , Greenland, John R. , Hellerstein, Marc K. , Fitch, Mark , Li, Kelvin W. , Esensten, Jonathan H. , Putnam, Amy , Lares, Angela , Nguyen, Vinh , Liu, Weihong , Bridges, Nancy D. , Odim, Jonah , Demetris, Anthony J. , Levitsky, Josh , Taner, Timuçin , Hellerstein, Marc , Feng, Sandy

Mayo Clinic

Science Translational Medicine | November 2, 2022 | Volume: 14 | Issue: 669 | Pages: No page available

10.1126/scitranslmed.abo2628 | PMID 36322627 Get It

Promoting immune tolerance to transplanted organs can minimize the amount of immunosuppressive drugs that patients need to take, reducing lifetime risks of mortality and morbidity. Regulatory T cells (T regs ) are essential for immune tolerance, and preclinical studies have shown their therapeutic efficacy in inducing transplantation tolerance. Here, we report the results of a phase 1/2 trial (ARTEMIS, NCT02474199) of autologous donor alloantigen–reactive T reg (darT reg ) therapy in individuals 2 to 6 years after receiving a living donor liver transplant. The primary efficacy endpoint was calcineurin inhibitor dose reduction by 75% with stable liver function tests for at least 12 weeks. Among 10 individuals who initiated immunosuppression withdrawal, 1 experienced rejection before planned darT reg infusion, 5 received darT regs , and 4 were not infused because of failure to manufacture the minimal infusible dose of 100 × 10 6 cells. darT reg infusion was not associated with adverse events. Two darT reg -infused participants reached the primary endpoint, but an insufficient number of recipients were treated for assessing the efficacy of darT regs . Mechanistic studies revealed generalized T reg activation, senescence, and selective reduction of donor reactivity after liver transplantation. Overall, the ARTEMIS trial features a design concept for evaluating the efficacy of T reg therapy in transplantation. The mechanistic insight gained from the study may help guide the design of future trials.